Reported 2 days ago
TransMedics Group, Inc. (TMDX) is gaining attention for its innovative warm perfusion technology that enhances organ transplant viability, addressing critical issues in organ utilization. Despite a significant stock price decline from its peak, the company is experiencing explosive growth with revenues projected to exceed $140 million in Q1 2025. Investors see strong long-term potential due to high barriers to entry and limited competition in a vital healthcare market, with forecasts suggesting a substantial upside by 2030.
Source: YAHOO